Fibrotic Interstitial Lung Disease Early Recognition and Strategic Therapy Study in China (FIRST): protocol for a prospective, multicentre registry study.

ABSTRACT:

Introduction

Interstitial lung diseases (ILDs) are a heterogeneous group of diseases characterised by varying degrees of inflammation and fibrosis. Among these, fibrotic interstitial lung disease (FILD) is receiving increasing attention. Many questions remain about FILD, such as identifying which ILDs are likely to progress to FILD, the timing of such progression, early recognition methods and biomarkers for FILD recognition and progression, highlighting the urgent need for a large multicentre FILD cohort to advance relevant studies.

Methods and analysis

The Fibrotic Interstitial Lung Disease Early Recognition and Strategic Therapy Study in China (FIRST) study is a prospective, multicentre cohort study of FILD conducted across 40 hospitals/centres in China, aiming to reveal

SUBMITTER: Wang S 

PROVIDER: S-EPMC12593440 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature